Abstracts tagged "biopsies"

Abstract Number: 646 • 2015 ACR/ARHP Annual Meeting
Sicca Syndrome in Rheumatoid Arthritis: Is It a Real Sjögren’s?
George Fragoulis¹, James Reilly¹, Shauna Kerr¹, Iain. B. McInnes¹ and Haralampos M. Moutsopoulos², ¹Institute of Infection, Immunity and Inflammation, College of Medicine, Veterinary Medicine and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ²Department of Pathophysiology, Medical School of Athens, Department of Pathophysiology, Athens, Greece
Background/Purpose: The histopathological hallmark and a major diagnostic criterion of Sjögren’s syndrome (SS) is the presence of periductal lymphocytic infiltrates in the labial minor salivary…
Abstract Number: 1960 • 2015 ACR/ARHP Annual Meeting
a Structured and Extensive Training Program on Vascular Ultrasound, Results in an Excellent Agreement Between Ultrasound and Temporal Artery Biopsy in the Diagnosis of Giant Cell Arteritis
Stavros Chrysidis¹, Ulrich Fredberg², Uffe Møller Døhn³, Tove Lorenzen⁴, Lene Terslev⁵, Knud Larsen⁶ and Andreas P Diamantopoulos⁷, ¹Department of Rheumatology, Hospital of Southwest Denmark, Esbjerg, Denmark, ²Department of Internal Medicine, Diagnostic Centre Region Hospital Silkeborg Denmark, Silkeborg, Denmark, ³Center for Rheumatology and Spine Diseases, Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet - Glostrup, University of Copenhagen, Glostrup, Denmark, ⁴Diagnostic Centre, Region Hospital Silkeborg, Silkeborg, Denmark, ⁵Copenhagen University Hospital at Glostrup, Copenhagen, Denmark, ⁶otolaryngology, Southwest hospital, Esbjerg, Denmark, ⁷Rheumatology, Haugesund Hospital for Rheumatic Diseases, Haugesund, Norway
Background/Purpose: There is an increased use of vascular ultrasound (US) for diagnosing giant cell arteritis (GCA). Consequently, extensive and structured training of ultrasonographers performing vascular…
Abstract Number: 1963 • 2015 ACR/ARHP Annual Meeting
Specialty of Provider Referring for Temporal Artery Biopsy Affects the Likelihood of Giant Cell Arteritis (GCA) Diagnosis
Lindsay Lally¹ and Robert F. Spiera², ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Rheumatology, HSS, New York, NY
Background/Purpose: Presenting signs/symptoms of GCA can be nonspecific and patients can initially present to a spectrum of clinical specialties. While temporal artery biopsy (TAB) is…
Abstract Number: 2160 • 2015 ACR/ARHP Annual Meeting
The Role of Ultrasound Compared to Biopsy of Temporal Arteries in the Diagnosis and Treatment of Giant Cell Arteritis: A Diagnostic Accuracy and Cost-Effectiveness Study
Raashid Luqmani¹, Ellen Lee², Surjeet Singh³, Michael Gillett², Wolfgang A. Schmidt⁴, Mike Bradburn², Bhaskar Dasgupta^5,6, Andreas P Diamantopoulos⁷, Wulf Forrester-Barker⁸, William Hamilton⁹, Shauna Masters¹⁰, Brendan McDonald¹¹, Eugene McNally⁸, Colin T. Pease¹², Jennifer Piper⁸, John Salmon¹³, Allan Wailoo², Konrad Wolfe¹⁴, Andrew Hutchings¹⁵ and TABUL Study group, ¹Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ²School of Health and Related Research, University of Sheffield, Sheffield, United Kingdom, ³1Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ⁴Medical Center for Rheumatology and Clinical Immunology Berlin-Buch, Immanuel Krankenhaus Berlin, Berlin, Germany, ⁵Rheumatology, Southend University Hospital, Essex, United Kingdom, ⁶Southend University Hospital, Essex, United Kingdom, ⁷Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, ⁸Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ⁹Primary Care, University of Exeter, Exeter, United Kingdom, ¹⁰Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Science, University of Oxford, Oxford, United Kingdom, ¹¹Department of Neuropathology and Ocular Pathology, Oxford University Hospitals NHS Trust, Oxford, United Kingdom, ¹²Rheumatology, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ¹³Ophthalmology, Oxford University Hospitals NHS Trust, Oxford, United Kingdom, ¹⁴Department of Pathology, Southend University Hospital, Essex, United Kingdom, ¹⁵Health Services Research Unit, London School of Hygiene and Tropical Medicine, London, United Kingdom
Background/Purpose: Giant cell arteritis (GCA) is a relatively common form of primary systemic vasculitis which if untreated can lead to permanent sight loss. It is…
Abstract Number: 2361 • 2015 ACR/ARHP Annual Meeting
Abatacept in the Treatment of Adult Dermatomyositis and Polymyositis: a Randomized, Treatment Delayed-Start Trial
Ingrid E. Lundberg¹, Anna Tjärnlund², Quan Tang³, Cecilia Wick², Maryam Dastmalchi⁴, Herman F Mann⁵, Jana Tomasová Studýnková⁵, Radka Chura⁶, Nicola J. Gullick⁷, Rosaria Salerno⁷, Eva Lindroos^3,8, Patrick Gordon⁶ and Jiri Vencovsky⁵, ¹Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, ²Rheumatology Unit, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden, ³Department of Medicine, Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, ⁴Department of Medicine, Solna, Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, ⁵Institute of Rheumatology, Prague, Czech Republic, ⁶Department of Rheumatology, King`s College Hospital NHS Foundation Trust, London, United Kingdom, ⁷Rheumatology, Department of Rheumatology, King`s College Hospital NHS Foundation Trust, London, United Kingdom, ⁸Department of Medicine, Rheumatology Unit, Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm, Sweden., Stockholm, Sweden
Background/Purpose: The aim of the study was to assess the effects of abatacept, a T cell blocking agent, on disease activity and on muscle biopsy…
Abstract Number: 2911 • 2015 ACR/ARHP Annual Meeting
Tubulointerstitial Involvement in Lupus Nephritis
Angela Pakozdi¹, Ravindra Rajakariar², Michael Sheaff³ and Dev Pyne¹, ¹Rheumatology, Barts Health NHS Trust, London, United Kingdom, ²Renal Medicine, Barts Health NHS Trust, London, United Kingdom, ³Histopathology, Barts Health NHS Trust, London, United Kingdom
Background/Purpose: Tubulointerstitial disease is frequent in lupus nephritis (LN) with immune deposits being present in up to one third of patients.[1,2] Lesions including interstitial infiltration,…
Abstract Number: 2912 • 2015 ACR/ARHP Annual Meeting
Concomitant Kidney Disease in Patients with Lupus Nephritis
Paul Hoover¹, Jose A. Gomez Puerta², Alexander Fine¹, Helmut Rennke³ and Karen H. Costenbader⁴, ¹Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Grupo de Inmunología e Inmunogenética, GICIG, Universidad de Antioquia, Medellín, Colombia, Medellín, Colombia, ³Pathology, Brigham and Women's Hospital, Boston, MA, ⁴Rheumatology, Immunology & Allergy, Brigham and Women's Hospital, Boston, MA
Background/Purpose: The most common and clinically and histologically best-characterized SLE kidney disease is lupus nephritis (LN). However, other forms of kidney disease can and do…
Abstract Number: 2917 • 2015 ACR/ARHP Annual Meeting
Combined Proliferative and Membranous Lupus Nephritis: Is the Prognosis Really Poor?
Ryota Sakai¹, Akiko Shibata¹, Kentaro Chino¹, Jun Kikuchi², Tsuneo Kondo¹, Ayumi Okuyama¹, Hirofumi Takei¹ and Koichi Amano¹, ¹Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama, Japan, ²Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama, Japan
Background/Purpose: Using light microscopy (LM) or immunofluorescence (IF), combined proliferative and membranous lupus nephritis (LN) is defined as an active proliferative class III/IV lesion and…
Abstract Number: 791 • 2014 ACR/ARHP Annual Meeting
Comparison of Clinical Manifestations in Different Histological Subsets of Biopsy-Proven Giant Cell Arteritis
Luigi Boiardi¹, Francesco Muratore¹, Alberto Cavazza², Giovanna Restuccia³, Pierluigi Macchioni¹, Giuseppe Germanò¹, Nicolò Pipitone¹, Gianluigi Bajocchi⁴ and Carlo Salvarani¹, ¹Rheumatology Unit, Arcispedale S Maria Nuova, Reggio Emilia, Italy, ²Pathology Unit, Arcispedale S Maria Nuova, Reggio Emilia, Italy, ³Rheumatology Unit, Arcispedale S Maria Nuova, Reggio Emilia, Italy, ⁴Rheumatology Unit, Arcispedale S Maria Nuova, Reggio Emilia, Japan
Background/Purpose: Temporal artery biopsy (TAB) showing transmural inflammation is considered the gold standard for the diagnosis of giant cell arteritis (GCA). In some cases of…
Abstract Number: 790 • 2014 ACR/ARHP Annual Meeting
Correlations Between Histopathological Findings and Clinical Manifestations in a Large Monocentric Cohort of Patients with Biopsy-Proven Giant Cell Arteritis
Luigi Boiardi¹, Francesco Muratore¹, Giovanna Restuccia², Alberto Cavazza³, Pierluigi Macchioni¹, Giuseppe Germanò¹, Nicolò Pipitone¹ and Carlo Salvarani¹, ¹Rheumatology Unit, Arcispedale S Maria Nuova, Reggio Emilia, Italy, ²Rheumatology Unit, Arcispedale S Maria Nuova, Reggio Emilia, Italy, ³Pathology Unit, Arcispedale S Maria Nuova, Reggio Emilia, Italy
Background/Purpose: Giant cell arteritis (GCA) is a vasculitis that involves large and medium sized arteries in patients older than 50 years. Temporal artery biopsy (TAB)…
Abstract Number: 788 • 2014 ACR/ARHP Annual Meeting
Fast-Track Diagnostic Procedure for Giant Cell Arteritis
Alojzija Hočevar¹, Ziga Rotar² and Matija Tomsic³, ¹Department of Rheumatology, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia, ²Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, ³Department of Rheumatology, BioRx.si, University Medical Centre Ljubjana, Ljubljana, Slovenia
Background/Purpose Giant cell arteritis (GCA) represents the most common primary vasculitis among adults aged 50 years or above. Recently, the national annual incidence rate in…
Abstract Number: 785 • 2014 ACR/ARHP Annual Meeting
Incidence, Prevalence and Survival of Biopsy-Proven Giant Cell Arteritis in Northern Italy
Mariagrazia Catanoso¹, Pierluigi Macchioni¹, Luigi Boiardi¹, Francesco Muratore¹, Giovanna Restuccia², Alberto Cavazza³, Ferdinando Luberto⁴ and Carlo Salvarani¹, ¹Rheumatology Unit, Arcispedale S Maria Nuova, Reggio Emilia, Italy, ²Rheumatology Unit, Arcispedale S Maria Nuova, Reggio Emilia, Italy, ³Pathology Unit, Arcispedale S Maria Nuova, Reggio Emilia, Italy, ⁴Statistical Service, Azienda Usl Reggio Emilia, Reggio Emilia, Italy
Background/Purpose: To investigate the incidence, prevalence and mortality of biopsy proven giant cell arteritis (GCA) over a 27-year period in a defined area of northern…
Abstract Number: 91 • 2014 ACR/ARHP Annual Meeting
Quantitative Proteomics Using Dimethyl Isotope Labeling for Comparison of Fresh Frozen Versus Formalin-Fixed, Paraffin-Embedded Tissue for Lupus Nephritis
Abhimanyu Amarnani¹, Joseph Capri², Puneet Souda³, David Elashoff⁴, Ivan Lopez⁵, Julian Whitelegge³ and Ram Singh¹, ¹Medicine/Rheumatology, University of California, Los Angeles, Los Angeles, CA, ²Pasarow Mass Spectrometry Laboratory, University of California, Los Angeles, Los Angeles, CA, ³The Pasarow Mass Spectrometry Laboratory, University of California, Los Angeles, Los Angeles, CA, ⁴Medicine/Statistics Core, University of California, Los Angeles, Los Angeles, CA, ⁵Head and Neck Surgery, University of California, Los Angeles, Los Angeles, CA
Background/Purpose Lupus nephritis (LN) progresses from mild focal inflammation, to diffuse proliferative nephritis, to fibrosis and end-stage renal disease. Though the understanding of LN has…
Abstract Number: 76 • 2014 ACR/ARHP Annual Meeting
Identification of Synovial Genes and Pathways Associated with Disease Progression in a Cohort of Early Symptomatic Osteoarthritis Patients Using a Transcriptomic Approach
Arjen B. Blom¹, Peter L. van Lent¹, Martijn H. van den Bosch², Hans Cats³, Frank H.J. van den Hoogen⁴, Floris P.J.G. Lafeber⁵, Wim B. van den Berg¹ and Peter M. van der Kraan¹, ¹Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands, ²Experimental Rheumatology (272), Radboud university medical center, Nijmegen, Netherlands, ³Hengstdal 3, Sint Maartenskliniek, Ubbergen, Netherlands, ⁴Rheumatology, Rheumatology Centre Sint Maartenskliniek and Radboud university medical center, Ubbergen (Nijmegen), Netherlands, ⁵Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: If and how the synovial activation that is observed in over 50% of osteoarthritis (OA) patients contributes to irreversible joint pathology, is not known.…
Abstract Number: 2787 • 2014 ACR/ARHP Annual Meeting
Identification of Urinary Biomarkers for Lupus Nephritis
Carolina Landolt-Marticorena¹, Stephenie Prokopec², Heather Reich³, James Scholey⁴, Carmen Avila-Casado⁵, Paul R. Fortin⁶, Paul Boutros² and Joan Wither⁷, ¹Rheumatology, Toronto Western Hospital, Toronto, ON, Canada, ²Ontario Institute for Cancer Research, Toronto, ON, Canada, ³Nephrology, University Health Network, Toronto, ON, Canada, ⁴Department of Medicine, The Toronto Western Hospital, Toronto, ON, Canada, ⁵Pathology, University Health Network, Toronto, ON, Canada, ⁶Rheumatology, Laval University, Division of Rheumatology, Centre de Recherche du CHU de Québec and Department of Medicine, Quebec City, QC, Canada, ⁷Immunology, University of Toronto, Toronto, ON, Canada
Background/Purpose: Lupus nephritis (LN) is a major determinant of morbidity and mortality in Systemic Lupus Erythematosus (SLE). Variability in clinical course, underlying renal injury, and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].